SEC Form 4 · accession 0001628280-26-058664
Crinetics Pharmaceuticals, Inc. · CRNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Tobin Schilke
Officer — Chief Financial & Infra. Ofcr.
Period of report
Aug 20, 2026
Accepted (ET)
Aug 24, 2026 · 4:52 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001658247
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Aug 20, 2026 | A | 471 | $0.00 | A | 79,427 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on September 1, 2027.
- F2Includes 835 shares acquired under the Issuer's Employee Stock Purchase Plan.